Policy and perspectives

Orla Mckay explores Spain’s first national HTA framework and what it means for value assessment, access, and future evidence requirements.

Can the EU’s reform agenda deliver on its aim of enhancing access and competitiveness, or do current efforts risk proving insufficient, or even counterproductive? Marietta Paraskevaides examines these key considerations.

Nick Stringfellow explores previous research in Central and Eastern Europe conducted by Lightning Health regarding pharmaceutical inequity, how this compares to the most recent published data, and the proposed tactics to mitigate growing disparities.

Ethan Shum highlights what the changes mean for regulatory strategy, implementation planning, and market continuity.

Marietta Paraskevaides explores how the U.S. MFN pricing framework could reshape drug pricing dynamics, generate significant healthcare savings and influence international market access strategies.

Sami Agush explores why Poland may emerge as a favourable launch destination for innovative medicines as manufacturers adapt to the implications of proposed US MFN pricing policies

Ethan Shum unpacks what these policy shifts mean in practice for market access teams operating in or entering China.

It was standing room only for James Whitehouse session at the World Evidence, Pricing and Access Congress 2026 - and plenty of questions afterwards.

Nick Stringfellow explores what manufacturers need to know to navigate these changes and plan their access strategies effectively.

Dr Bhakti Dhingra reflects on the lessons and key insights from 2025.

Marietta Paraskevaides talks about the implications of the EU Joint Clinical Assessment for rare diseases